JERUSALEM--(BUSINESS WIRE)--Oramed Pharmaceuticals, Inc. (ORMP.OB, www.oramed.com) announced today the signing of an agreement with OnQ consulting, a clinical research organization (CRO) located in Johannesburg, South Africa, to conduct Phase 2B clinical trials on its oral insulin capsules. The study is intended to evaluate the safety, tolerability and efficacy on diabetic type 2 volunteers, using Oramed’s oral insulin capsule. It is anticipated that this study will be conducted over several months, and the 30 subjects will each receive the treatment for a period of 6 weeks.
